- t2cure’s cell therapy is available through cooperating clinical centres
- t2cure cooperates with experienced partners in research and in the industry.
- t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
- t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.
Latest News
t2cure’s Cellular Therapeutic Receives Orphan Drug Designation 06.24.2010
Frankfurt, Germany, June 24, 2010 – t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the FDA has granted orphan drug designation to t2c001 for the treatment of...